Skip to main content

Posters

Recent Posters

Posters  —  1 July Jul 2022

FDA-cleared elio™ tissue complete assay provides rapid, accurate, and actionable insights to guide targeted cancer therapies with a path to reimbursemen

Read More about FDA-cleared elio™ tissue complete assay provides rapid, accurate, and actionable insights to guide targeted cancer therapies with a path to reimbursemen
Posters  —  18 June Jun 2022

Common Malignant Spontaneous Neoplastic Findings in SD Rats Used in Nonclinical Research Studies

Read More about Common Malignant Spontaneous Neoplastic Findings in SD Rats Used in Nonclinical Research Studies
Posters  —  18 June Jun 2022

Assessment of the "Biological or Toxicological Relevance" of Clinical Pathology Changes

Read More about Assessment of the "Biological or Toxicological Relevance" of Clinical Pathology Changes
Posters  —  18 June Jun 2022

Historical Control Background Incidence of Spontaneous Nonneoplastic Lesions of Sprague Dawley Rats Used in 104-Week Toxicity Studies

Read More about Historical Control Background Incidence of Spontaneous Nonneoplastic Lesions of Sprague Dawley Rats Used in 104-Week Toxicity Studies
Posters  —  18 June Jun 2022

Common Spontaneous Benign Neoplastic Findings in SD Rats Used in Nonclinical Research Studies

Read More about Common Spontaneous Benign Neoplastic Findings in SD Rats Used in Nonclinical Research Studies
Posters  —  13 June Jun 2022

In Vitro Cytotoxicity in MucilAir™ Tissues Exposed to Whole Aerosol from a Combustible Cigarette and Electronic Nicotine Delivery System

Read More about In Vitro Cytotoxicity in MucilAir™ Tissues Exposed to Whole Aerosol from a Combustible Cigarette and Electronic Nicotine Delivery System
Posters  —  2 June Jun 2022

Mutational landscape and clinical characterization of over 17000 patient samples with myeloid malignancies using real world data

Read More about Mutational landscape and clinical characterization of over 17000 patient samples with myeloid malignancies using real world data
Posters  —  2 June Jun 2022

Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD L1 IHC

Read More about Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD L1 IHC
Posters  —  2 June Jun 2022

LAG3 transcriptomic expression correlates with high levels of PD 1, PD L1, PD L2, and CTLA 4 checkpoints and with high tumor mutational burden across cancers

Read More about LAG3 transcriptomic expression correlates with high levels of PD 1, PD L1, PD L2, and CTLA 4 checkpoints and with high tumor mutational burden across cancers
Posters  —  1 June Jun 2022

Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance

Read More about Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance
Posters  —  16 May May 2022

In Vitro Characterization of CD19 CAR T Cells Derived by Electroporation of mRNA

Read More about In Vitro Characterization of CD19 CAR T Cells Derived by Electroporation of mRNA
Posters  —  16 May May 2022

Development of an In Vitro Assay for Assessment of IL-2 Independent CAR T Proliferation

Read More about Development of an In Vitro Assay for Assessment of IL-2 Independent CAR T Proliferation